Investigators at MD Anderson reported early clinical activity for VT3989, a first‑in‑class YAP–TEAD inhibitor, in heavily pretreated patients with refractory mesothelioma and other solid tumors. The Phase 1/early‑phase dataset showed tolerability and signs of tumor control in a subset of patients, supporting further development in mesothelioma where treatment options remain limited. The mechanism targets Hippo pathway signaling; for readers, YAP–TEAD is a transcriptional complex implicated in tumor growth and therapy resistance.